entertainment -WSS

entertainment

author：focus 2025-09-30 23:19:34 - browse：1

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： EQRx, failed developer of low

WSS

No plane should take off without an EpiPen onboard

Why CTE doesn’t keep Americans from enjoying the Super Bowl

The CDC's new social media misinformation war

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

AstraZeneca stays mum on Medicare drug pricing negotiations

The CDC's new social media misinformation war

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Updated Covid vaccine has 54% effectiveness, new study suggests

Trump demands the U.S. pay no more for drugs than other countries … again

NIH launches clinical trials and new research office for long Covid

Apple is now the first public company to be valued at $3 trillion

Mega Millions pot grows to $1.25 billion after no winner

At least 13 dead in Texas as scorching temps continue

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

entertainment

New safety details link Apellis eye drug to rare cases of blindness

Mitch McConnell episode has important public health takeaway

Adults seen as increasingly susceptible to measles

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Sage hopes for a blockbuster in antidepressant now before FDA

National panel will explore requiring free Covid tests

hotspot

explore

entertainment

leisure time